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ABSTRACT:Hexose-6-phosphate dehydrogenase (H6PD) produces reducedNADPH in the endoplasmic reticulum (ER)
lumen. NADPH constitutes a cofactor for many reducing enzymes, and its inability to traverse biologic membranes
makes in situ synthesis of NADPH in the ER lumen indispensable. The H6PD gene is amplified in several types of
malignancies, and earlier work pointed toward a potential involvement of the enzyme in cancer cell growth. In the
presentstudy,wedemonstratedapivotal roleofH6PDinproliferationandmigratorypotentialof3humanbreast cancer
cell lines. Knockdown ofH6PDdecreased proliferation andmigration in SUM159,MCF7, andMDA-MB-453 cells. To
understand the mechanism through which H6PD exerts its effects, we investigated the cellular changes after H6PD
silencing inSUM159cells.KnockdownofH6PDresulted inan increase inERlumenoxidation, anddown-regulationof
manycomponentsof theunfoldedprotein response, including the transcription factors activating transcription factor-4,
activating transcription factor-6, split X-box binding protein-1, and CCAAT/enhancer binding protein homologous
protein. This effect was accompanied by an increase in sarco/endoplasmic reticulumCa2+-ATPase-2 pump expression
and an decrease in inositol trisphosphate receptor-III, which led to augmented levels of calcium in the ER. Further
characterization of the molecular pathways involving H6PD could greatly broaden our understanding of how the ER
microenvironmentsustainsmalignantcellgrowth.—Tsachaki,M.,Mladenovic,N., Sˇtambergova´,H.,Birk, J.,Odermatt,
A. Hexose-6-phosphate dehydrogenase controls cancer cell proliferation and migration through pleiotropic effects on
theunfoldedprotein response, calciumhomeostasis, and redoxbalance. FASEB J. 32, 2690–2705 (2018).www.fasebj.org
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Hexose-6-phosphate dehydrogenase (H6PD) (1) is the
only well-characterized enzyme found responsible to
date for producing reduced NADPH in the lumen of the
endoplasmic reticulum (ER), through conversion of glu-
cose 6-phosphate to 6-phosphogluconate. The same reac-
tion is performed in the cytosol by glucose-6-phophate
dehydrogenase (G6PD), representing the first step of the
pentose phosphate pathway. In contrast to its cytosolic
counterpart, H6PD can also perform the second step of
this pathway, acting as a 6-phosphogluconolactonase (2).
Because NADPH is regarded to be impermeable through
the ER membrane (3), a separate NADPH pool is present
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within the ER. NADPH is widely used as a cofactor for
reducing enzymatic reactions in the cytosol. In contrast,
the relevance of luminal NADPHproduction byH6PD
has not been sufficiently explored. The only enzyme
that has been undeniably shown to use NADPH as a
cofactor in the ER lumen is 11b-hydroxysteroid de-
hydrogenase type (11b-HSD)-1 (4, 5), catalyzing the
oxoreduction of the inactive glucocorticoid cortisone
to its potent equivalent cortisol (6). Mice deficient in
H6PD (H6PD2/2) present with skeletal muscle defects
that are independent of 11b-HSD1, indicating un-
known functions of H6PD for cell physiology (7, 8).
Muscles from H6PD2/2 mice compared to wild-type
tissues exhibited an increase in 78 kDa glucose-
regulated protein (Grp78 or Bip) levels, which is in-
volved in both protein folding and the unfolded-protein
response (UPR) pathway. In addition, the levels of the
UPRmediator split X-box-bindingprotein (sXBP)-1were
increased, and microarray analysis showed altered ex-
pression of several UPR proteins. Furthermore, muscles
from H6PD2/2 mice showed decreased expression of
the sarco/ER Ca2+-ATPase (SERCA), which is re-
sponsible for pumping calcium from the cytosol into the
ER at the expense of ATP.
Recently, down-regulation of H6PD with short in-
terfering (si)RNAs in the murine cancer cell lines CT26
(colon) and 4T1 (breast) correlated with a reduction in
the overall glucose uptake, as well as a decreased cell
proliferation (9). In addition, H6PDwas identified in a
proteome-wide screening as a target of the poly(ADP-
ribose) polymerase (PARP) inhibitors rucaparib and
niraparib (10). In this report, knockdown of H6PD in-
creased apoptosis in a triple-negative breast cancer cell
line (CAL-51), where the researchers observed a con-
comitant increase in PARP-1 and caspase-3 cleavage.
However, these findings could not be reproduced in
another triple-negative breast cancer cell line (MDA-
MB-468). The results of the above experiments pointed
toward apotential role ofH6PD in cancer cell physiology
and a possible link between H6PD function and energy
metabolism. The H6PD gene is amplified in 3–4% of
pancreatic, sarcomatous, and ovarian tumors and in 1–2%
of breast, lung adenocarcinoma, and melanoma tumors,
supporting a role of the enzyme in cancer cell growth.
In the present study, we showed that H6PD promotes
cancer cell proliferation by using 3 different breast cancer
cell models, each representing one of the main molecu-
lar subtypes of breast cancer: the triple-negative cell line
SUM159 [does not express progesterone receptor (PR2),
estrogen receptor (ER2), nor the Her2 receptor (Her22)],
the PR+, ER+, Her22 cell line MCF7, and the PR2, ER2,
Her2+ cell line MDA-MB-453. We further demonstrated
that H6PD knockdown dramatically reduces migration
in all cell lines tested. Subsequently, we attempted
to elucidate the mechanism through which H6PD in-
fluences cancer cell growth. Our results suggest a
major role of H6PD in regulating UPR signaling pro-
teins, as well as ER calcium balance. H6PD depletion
also caused an increase in ER oxidation and a signifi-
cant decrease in cellular oxygen consumption rate.
The above findings highlight, for the first time, the
consequences of NADPH depletion within the ER
for cancer cell physiology, paving the way for further in-
vestigations into the ER-related molecular pathways that
promote malignant cell proliferation and migration.
MATERIALS AND METHODS
Chemicals
Unless otherwise stated, all chemicals were purchased from
Millipore-Sigma (Buchs, Switzerland).
Cell lines and transfections
The SUM159, MCF7, andMDA-MB-453 cell lines were acquired
from American Type Culture Collection (Manassas, VA, USA),
tested monthly for mycoplasma contamination, and cultivated
under standard conditions (37°C, 5% CO2). SUM159 cells were
cultured inHam’sF12nutrientmixture (ThermoFisher Scientific,
Waltham, MAUSA), supplemented with 5% fetal bovine serum
(FBS) and 5 mg/ml bovine insulin (cat. no. I6634; Millipore-
Sigma) (11–14). MCF7 cells were cultured in DMEM containing
2 mM L-glutamine, 4.5 g/L glucose, 10% FBS, and nonessential
aminoacidmixture.MDA-MB-453cellswerecultivated inRPMI-
1640mediumsuppliedwith 10%FBS.All cell culturemediawere
supplemented with 100 U/ml penicillin, 0.1 mg/ml streptomy-
cin, and 10 mM hydroxyethyl piperazineethanesulfonic acid
(HEPES) buffer (pH 7.4).
For siRNA delivery Lipofectamine RNAiMax (Thermo Fisher
Scientific) was used. Typically, 50 pM siRNA and 2.5 ml Lipofect-
amine reagent were used per 300,000 cells. The target sequence of
the mock siRNAwas 59-UGGUUUACAUGUUUUCUGA-39 and
of the H6PD siRNA was 59-GGGCUACGCUCGGAUCUUG-39
(GE Dharmacon, Lafayette, CO, USA).
Lipofectamine 2000 (Thermo Fisher Scientific) was used for
DNA transfection of the SUM159 cell line; 2.5 mg plasmid DNA
and 5 ml reagent were used per 180,000 cells, whichwere seeded
the day before transfection. The medium was exchanged with
fresh culture medium 6 h after transfection.
Protein expression analysis
Theprocedures for cell lysis, protein extraction, andWestern blot
analysis have been previously described (15). Antibodies against
the following proteinswere used:H6PD (HPA004824;Millipore-
Sigma); proteinkinaseR-likeERkinase (PERK; 3192 ), eukaryotic
initiation factor (eIF)-2a (9722S), phospho-(p)eIF2a (119A11),
ATF4 (11815S), ATF6 (65880S), sXBP-1 (12782S), and CCAAT/
enhancer binding protein homologous protein (CHOP; 2895S; all
fromCell Signaling Technology,Danvers,MA,USA); Grp94 (16)
and Grp78 (610978; BD Biosciences, San Jose, CA, USA); pro-
tein disulfide isomerase (PDI; Ab2792; Abcam Inc, Cambridge,
UnitedKingdom); ERp44 (17), ERp72 (Stressgen, SanDiego,CA,
USA); calreticulin (2891S; Cell Signaling Technology), calnexin
(SAB4503258; Millipore-Sigma); SERCA2 (cat. no. MA3-919;
Thermo Fisher Scientific); actin (sc-1616) and inositol
trisphosphate-3 receptor (IP3R)-III (sc-7277; both from Santa
Cruz Biotechnology, Dallas, TX, USA); and a-tubulin
(GTX628802; GeneTex, Irvine, CA, USA). All antibodies were
used at a concentration of 1 mg/ml, except for those against
CHOP and IP3RIII, which were used at 2 mg/ml, and those
against calnexin, PDI, and a-tubulin, which were used at
0.25 mg/ml. For every sample, 25–30 mg total protein extract
was loaded on polyacrylamide gels.
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Real-time quantitative PCR and gene
expression analysis
To assess mRNA levels, total RNA was extracted with the TRI
Reagent (Millipore-Sigma), andcDNAwassubsequentlyproduced
by reverse transcription with Maloney murine leukemia virus re-
verse transcriptase (Promega, Madison, WI, USA). The KAPA
SYBR Fast Kit (Millipore-Sigma) was used for quantitative PCR
(qPCR) analysis, and the reactions were performed in the Rotor
Gene Real-Time Cycler (Corbett Research, Sydney, New South
Wales, Australia). Datawere normalized to the expression levels of
the endogenous control gene peptidyl-prolyl cis-trans isomerase
A according to the 22DDCt method for relative quantification
(18). The primers are listed in Supplemental Table 1.
Real-time cell proliferation assay
For real-time, impedance-based monitoring of cell proliferation,
the xCELLigence real-time cell analyzer (RTCA) DP instrument
was used (ACEA Biosciences Inc., San Diego, CA, USA). Cells
were transfected with siRNAs or left untreated and seeded on
an E-Plate View 16 featuring microelectrode sensors. After pre-
liminary evaluation of optimal cell density, 5,000, 7,500, and
10,000 cells were seeded per well, of the SUM159, MCF7, and
MDA-MB-453 cell lines, respectively. Quadruplets of every
samplewereprepared, and signal detectionwas registered every
30 min over a period of 96 h. Data analysis was performed with
the RTCA software 2.0.
High-content imaging
After siRNA transfection on 96-well plates, cellswere fixed at the
indicated time points with 4% formaldehyde for 12 min and
washed 3 times with PBS; the nuclei were stained with 5 mg/ml
Hoechst-33342 (Thermo Fisher Scientific) for 15 min. After
4washeswith PBS, the number of nuclei was quantifiedwith the
ArrayScan high-content imaging system (Thermo Fisher Scien-
tific). For each of at least 3 independent experiments, every
sample was represented in quadruplets, and valid objects were
measured in 14 randomly selected fields.
ATP measurements
ATP levels were measured with the CellTiter-Glo Luminescent
assay (Promega), according to themanufacturer’s instructions. In
brief, 5000 SUM159 cells were seeded in triplicate on a 96-well
plate. At different time points, luminescence wasmeasured after
addition of the CellTiter-Glo Reagent with a SpectraMax-L
luminometer (Molecular Devices, Devon, United Kingdom).
Cell migration assay
Cells were transfected with siRNAs on a 35-mm plate and
reseeded 48 h after transfection into the top chamber of a 24-well
insert (pore size 8 mm; Transwell; Corning Inc., Lowell, MA,
USA) at a density of 7,500, 20,000 and 30,000 for the SUM159,
MCF7, and MDA-MB-453, respectively. The bottom chamber
contained normal cell culture medium, and the top chamber
contained medium supplemented with 1% FBS for the SUM159
or 0.5% FBS for the MCF7 and MDA-MB-453 cells. After a 24 h
incubation, the cells were stained for 20 min with 0.1% crystal
violet (w/v in 25%methanol). Cells on the top of the membrane
were removedwith a cotton swab, and the remaining cells on the
bottom were imaged under a light microscope with a 320 ob-
jective (Axiovert 100; Zeiss GmbH, Feldbach, Switzerland). Ten
fields were captured per sample, and stained cells were counted
using the Cell Counter plugin of ImageJ software (National In-
stitutes of Health, Bethesda, MD, USA).
Cell adhesion assay
Cellswere seededat adensityof25,000perwellon96-well plates,
uncoated or coated with 50 mg/ml fibronectin. After incubation
for 40 min at 37°C, the plate was shaken at 600 rpm for 1.5 min.
After 2 washes with PBS, the cells were fixed for 12minwith 4%
formaldehyde, washed twice with PBS, and stained with crystal
violet for 5min. SDS 1%was added, and the platewas incubated
with shaking at 400 rpm for 10 min, before absorbance was
measured ina spectrumwindowof595–600nmwith theSynergy
HTmicroplate reader (BioTek Instruments,Winooski, VT,USA).
Cell cycle analysis
For analysis of the cell cycle phases, cells were trypsinized and
fixed in 70% ethanol for 30 min at 4°C. After treatment with
100mg/mlRNaseAtreatment, stainingwasperformedin40mg/ml
propidium iodine dissolved in PBS. The cells were then ana-
lyzed by fluorescence-activated cell sorting (FACS) with the
FACSCanto II (BDBiosciences). Datawere analyzedwith V9/X
software (FlowJo, Ashland, OR, USA).
Live measurements of ER lumen oxidation status
To assess the degree of oxidation in the lumen of the ER, the
reduction–oxidation–sensitivegreen fluorescentprotein (roGFP)1-
iEER sensor was used (19). Cells were transfected with siRNAs
and seeded on 35 mm glass-bottom dishes (MatTek, Ashland,
MA, USA). After 24 h, cells were transfected with the roGFPiEER
plasmid, and image analysis followed 48 or 72 h after siRNA
delivery. For determination of sensor oxidation, cells were
washed twice with HEPES buffer (pH 7.4) and imaged with
the 360 oil-immersion objective (NA 1.40) of a FluoView1000
confocal laser scanning microscope (Olympus, Tokyo, Japan).
The 405 and 440 nm laser diodes were used to excite the sensor,
and the emission windowwas set at 505–605 nm. The image size
was 512 3 512 pixels, and the pinhole was adjusted to a com-
pletely open setting. The acquisition of the emitted fluorescence
signals was sequential. Images were captured at steady state,
2 min after addition of 5mMdiamide for complete oxidation and
5 min after addition of 20 mMDTT for complete reduction of the
sensor. Three independent experiments were performed, and an
average of 10 cellswere analyzedper sample in every experiment.
In each cell 1–2 regions of interest were selected for analysis of the
fluorescence emission intensities at 405 and 440 nm. Background
signal was subtracted from all the acquired values. After calcu-
lation of the ratio of intensities at steady state, after complete ox-
idation and complete reduction, the oxidation value was
calculated based on Eq. 1:
OxDroGFP2 ¼ R2RredImin
Imax
ðRox2RÞ þ ðR2RredÞ
(1)
whereOxDroGFP2 is the oxidationvalueof roGFP-2;R,Rred, and
Rox are the 405:440 nm emission ratios at steady state or after
reduction or oxidation, respectively; and Imin and Imax corre-
spond to the fluorescence intensities of the fully oxidized and
reduced sensor after excitation at 440 nm.
Measurement of mitochondrial superoxide levels
To evaluate mitochondrial superoxide levels, we used the specific
indicatorMitoSoxRed(ThermoFisherScientific).Cellswere seeded
on 96-well plates, and, at the desired time point,werewashedwith
charcoal-treated medium and stained with Hoechst 33342 for
30 min at 37°C. After 1 wash with PBS and 1 wash with charcoal-
treated medium, 2.5 mM MitoSox Red was added. Fluorescence
intensitiesweremeasured over timewithArrayScan high-content
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imaging, as previously described. Because measurements were
performed in living cells, the imaging chamber was humidified
and maintained at an environment of 37°C and 5% CO2.
Dynamic in vivo calcium measurements in the
ER lumen
ToassessER luminal calciumcontent, the fluorescence resonance
energy transfer (FRET)-based Cameleon sensor D1ER, which is
specifically targeted to the ER, was used (20, 21). Cells were
transfectedwith siRNAs and seeded on glass coverslips. Twenty-
fourhoursafter siRNAtransfection, the cellswere transfectedwith
the plasmid containing the D1ER coding sequence. Analysis of
samples commenced 42 or 68 h after siRNA transfection and,
according to the timeneeded for samplepreparationand imaging,
continued up to 46 or 72 h, respectively. Cells were washed twice
with 2ml 13HBSS (prepared from a 103 stock solution of HBSS,
cat. no. 14185052; Thermo Fisher Scientific), supplemented with
20 mM HEPES buffer (pH 7.4), 2 g/L glucose, 0.49 mM MgCl2,
0.45 mM MgSO4, and 0.3 mM CaCl2 (henceforth referred to as
HHBSS). This concentration of CaCl2was based on that present in
the culturemediumof theSUM159cells andhad tobeadjusted for
each cell line. Coverslips were then transferred in a perfusion
chamber, where washes and treatments were performedwith the
help of the P720 peristaltic pump (Instech Laboratories, Plymouth
Meeting, PA,USA). The360 oil-immersion objective (NA 1.40) of
the FluoView1000 confocal laser scanningmicroscope (Olympus)
was used for imaging and simultaneous acquisition of emission
wavelengths for cyan fluorescent protein (CFP) and FRET after
excitationwith the 440 nm laser diodewas performed. All images
were acquired in 30 s increments. Resting calcium was assessed
after acquisition of 12–15 images at steady state. Subsequently,
imageacquisitionwaspaused, andcellswerewashed3 timeswith
2mlHHBSSwithoutCaCl2.Cellswere then incubated in the same
buffer supplemented with 10 mM ionomycin and 5 mM EGTA,
and 15 more images were acquired. This treatment results in
minimum concentration of calcium in the ER lumen. Data acqui-
sition was again paused, and the cells were washed once with
HHBSS without CaCl2 and incubated in HHBSS without CaCl2,
supplementedwith2mMMgCl2and100mMATPfor1min.Cells
were thenwashed oncewith 2mlHHBSS (containing CaCl2) and
incubated with HHBSS, containing an additional 5 mM CaCl2,
10 mM ionomycin, 2 mM MgCl2, and 100 mM ATP, to achieve
maximum calcium concentration in the ER and thus sensor satu-
ration. Fifteen more images were captured immediately after this
treatment. The FRET ratio was calculated using Eq. 2:
Ratio ¼ FRETintensity2 FRETbackground

CFPintensity
2CFPbackground

(2)
From the ratio at steady state (R), after ER calcium depletion
(Rmin) and maximum ER calcium loading (Rmax), the DR was
calculated using Eq. 3:
DR ¼ ðR2RminÞ=ðR2RmaxÞ3 100 (3)
Three independent experimentswereperformed, and 35–40 cells
per condition were imaged in total, from which 1–2 regions of
interest were typically analyzed.
Cytosolic calcium measurements
Cell were seeded and transfected with siRNAs in glass-bottom
dishes.After72h, stainingsolutionwasadded [F14201,2.2mg/ml
FLUO-4AM(ThermoFisher Scientific) and2.5mMprobenecid in
completemedium], followedby incubation for 1h at 37°C.After 3
washes with HEPES buffer, fluorescence was monitored in real
time using an inverted microscope (DMI4000 B; Leica
Microsystems, Buffalo Grove, IL, USA). Once the signal was
stabilized, 10mMcarbachol (Cch)was added, and fluorescence
was monitored until return to baseline. For fluorescence in-
tensity measurements, an entire field visualized under the320
objective was chosen, and signal was quantified with Suite X
software (LAS X; Leica).
Measurements of oxygen consumption rate and
extracellular acidification rate
The oxygen consumption rate (OCR) and extracellular acidi-
fication rate (ECAR) were measured in real-time using the
Seahorse XF96 analyzer (Agilent Technologies). Cell line
characterization was performed according to the manufacturer’s
instructions, to achieve optimal cell densities and determine
the concentration of carbonyl cyanide-4-(trifluoromethoxy)
phenylhydrazone (FCCP) to be applied. Cells were trans-
fected with siRNAs and seeded in 6 replicates for each sample
on a 96-well microplate. On the day of the measurement, cells
were washed twice with XF base medium (Agilent Technolo-
gies) and supplemented with the appropriate amounts of
pyruvate, glutamine, and glucose, according to the culture
medium concentrations of each cell line, and the pH was
adjusted to 7.4. The cells were incubated in this medium for
1 h in an incubator without CO2 before transfer to the XF96
instrument. Three measurements of OCR and ECAR were
performed before injection of 1 mM oligomycin and 0.5 mM
FCCP, followed by 5 more measurements. During the ex-
periment, the cells were kept in a humidified chamber at
37°C, under normal oxygen conditions. Datawere processed
using the Wave 2.0 software and the XF Cell Energy phe-
notype report generator (Agilent Technologies).
Indirect immunofluorescence
Experiments of indirect immunofluorescence were essentially
performed as in Tsachaki et al. (22). For actin visualization,
phalloidin-FITCwas used (Enzo Life Sciences, Farmingdale,NY,
USA) in 1:150 dilution. The anti a-tubulin antibody was the one
described inWestern blot analysis andused in 1:200 dilution. All
images were acquired with the 360 objective of the FluoView
1000 confocal laser scanning microscope (Olympus).
Statistical analysis
Dataarepresentedasmeans6 SD, and thestatistical significanceof
differences between treatments and control conditions were esti-
matedbya2-tailedStudent’s t test inPrism5software (GraphPad,
La Jolla, CA, USA). Significance was accepted at P, 0.05.
RESULTS
Knockdown of H6PD reduces proliferation
and migration in the SUM159, MCF7, and
MDA-MB-453 breast cancer cell lines
Toexamine the impactofH6PDoncancer cellproliferation,
we first silenced its expression by using specific siRNAs in
the SUM159, MCF7, and MDA-MB-453 cell lines. Sub-
sequently, we performed Western blot analysis at 24, 48,
and 72 h after siRNA delivery, to evaluate the efficiency of
protein level reduction over time (Supplemental Fig. 1). In
SUM159 cells, a reduction in H6PD levels at 24 h after
siRNA treatment was not observed in all experiments, in
contrast to the reduction inMCF7 andMDA-MB-453 cells.
We observed discernible H6PD down-regulation at 48 h
after H6PD siRNA delivery compared to mock siRNA or
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nontransfected controls,whichwasmostprominent at 72h
of siRNA treatment, in all cell lines.
After confirming the knockdown efficiency in our cell
models, we down-regulated H6PD and monitored cell
proliferation with the xCelligence RTCA. The transfection
procedure did not affect proliferation, as observed when
comparing nontransfected and mock siRNA-transfected
cells (Fig. 1A, B). In SUM159 cells, we observed a decrease
in cell proliferation over time after H6PD siRNA delivery
compared to mock-transfected cells, starting 48–50 h after
knockdown. The same effect was observed in MCF7 cells
42–48 h and in MDA-MB-453 cells 32–40 h after knock-
down (Fig. 1A). To investigate whether components pre-
sent in the serum would further influence the effect of
H6PD down-regulation on cell proliferation, we per-
formed the same experiments in SUM159 andMCF7 cells
using one-fourth of the amount of serum present in their
normal medium (Fig. 1B; low serum).We did not observe
any significant difference compared to the experiments in
which normal serum concentrations were used. As stated
Figure 1. Down-regulation of H6PD reduces cell proliferation in SUM159, MCF7, and MDA-MB-453 cells. A, B) Real-time
measurements of cell proliferation using a cell analyzer for SUM159, MCF7, and MDA-MB-453 cells under normal culture conditions
(A), for SUM159 and MCF7 cells under reduced serum conditions, or for MCF7 cells under reduced glucose conditions (B). C–E) In
each case, 1 of 3 independent measurements is shown. Red curves: untransfected control cells; blue curves: mock siRNA-treated cells;
green curves: H6PD siRNA-transfected cells. Measurement of number of cells over time (24, 48, and 72 h) estimated by Hoechst nuclear
staining and high-content imaging in the SUM159 cell line (normal culture and reduced serum conditions) (C), in MCF7 cells (normal
culture, reduced serum, and reduced glucose conditions) (D), and in MDA-MB-453 cells (E). Ctrl, control (no transfection). Values
represent the mean of at least 3 independent experiments; error bars 5 SD. *P , 0.05, **P , 0.01, ***P , 0.001 vs. mock siRNA.
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above, it has been suggested that H6PD is involved in
cellular glucose uptake (9), which would mean that a de-
crease in extracellular glucose concentration could de-
teriorate theH6PDeffect oncellproliferation.Nonetheless,
lowering the glucose concentration from 4.5 to 1 g/L did
not cause any further reduction of MCF7 cell proliferation
upon H6PD knockdown (Fig. 1B). The effect of lower
glucose couldnotbe testedon theother 2 cell lines, because
the corresponding media were not available. To validate
the above findings by adifferent experimentalmethod,we
performed a series of end-point experiments in which we
counted nuclei after Hoechst 33342 dye staining (corre-
lated directly with cell number) using fluorescence high-
content imaging after 24, 48, and 72 h of siRNA treatment.
The results are similar to those obtained with RTCA,
demonstrating a considerable difference innumber of cells
after H6PD knockdown compared to mock-transfected
cells and reaching statistical significance at 72hafterH6PD
silencing for all 3 breast cancer cell lines tested (Fig. 1C–E).
Comparison of the number of cells at 72 h after H6PD
knockdownwith that for mock-transfected cells at 72 h in
normal culture conditions and in reduced serum for
SUM159 (76.96 1.9% in normal serum and 66.96 1.9% in
reduced serum) and MCF7 cells (70.6 6 5.7% in normal
serum and 64.1 6 5.9% in reduced serum) or glucose
concentrations for MCF7 cells (70.66 5.7% in 4.5 g/L and
69.8 6 5.4% in 1 g/L) showed no significant difference
(comparison not shown).
To investigate whether the reduced number of cells
upon H6PD silencing was related to defects in the cell
cycle,weexamined the expressionofkey regulatoryCCNs
48 h after siRNA treatment of SUM159 cells. At this
time point, cells still proliferate actively, and initial alter-
ations in cell cycle progression can be captured.We found
that the mRNA levels of CCNE1 and E2 (facilitating S
transition), CCNA2 (regulating Sphase andmitotic entry),
and G2/mitotic CCNB1 were greatly reduced after H6PD
down-regulation (Supplemental Fig. 2A). The levels of
G1-specific CCND1 were not significantly changed, al-
though a trend increase was observed. However, mRNA
levels of the CCN-dependent kinase inhibitors p21 (gene
CDKN1A) and p27 (gene CDKN1B), which control pro-
gression of the cell cycle at the G1 checkpoint, were in-
creased. In accordance, cell cycle analysis at 48 h after
H6PD down-regulation, showed a higher percentage of
cells at the G1 phase (Supplemental Fig. 2B). Increased
accumulation of cells at this stage could eventually lead to
a reduced number of cells after H6PD silencing.
Besides increased proliferation potential, a central as-
pect of tumor cell physiology is their ability tomigrate and
invade distant tissues. To evaluate whether H6PD is in-
volved in cancer cell migration, we performed a cell mi-
gration assay (Transwell) with a serum gradient as a
chemoattractant. H6PD knockdown led to an 80% de-
crease inmigrationof SUM159 cells,whichhad thehighest
migratory potential of the 3 cell lines analyzed (Fig. 2A). A
significant decrease in cell migration was also observed in
the MCF7 andMDA-MB-453 cells.
Altered migration may be related to changes in cell
adhesion. To explore this possibility, we studied the im-
pact of H6PD on the attachment to fibronectin-coated
dishes of SUM159 cells and found a significant increase
in adhesion upon H6PD silencing (Fig. 2B). To examine
whether this effect derives from altered expression of
proteins responsible for cell interaction with the extracel-
lular matrix, we examined the expression of matrix met-
alloproteinases (MMPs), focusing on theMMPs that were
highly expressed in our cell model. Forty-eight hours after
transfectionofH6PDsiRNAs inSUM159 cells, the levels of
MMP1 were decreased, consistent with the observed in-
crease in cell adhesion (Fig. 2C).MMP1 is transcriptionally
activated by b-catenin (gene name CTNNB1), which was
also found to be down-regulated (23). Reduced b-catenin
levels could lead to attenuated expression of other genes
that promote cell migration, as well as changes in the in-
tegrity of the cytoskeleton (24). In addition, MMP2 levels
remained the same, whereas the levels of MMP14 were
surprisingly increased. In fact, at 72 h after H6PD down-
regulation, all MMPs tested were up-regulated, which
could be explained through the existence of a compensa-
tory mechanism. Next, we sought to determine whether
defects in cytoskeletal organization account for reduced
migration. For this purpose, we examined the pattern of
actin filaments as visualized after binding to phalloidin-
FITC, and encountered no difference between mock and
H6PD siRNA-transfected SUM159 cells (Supplemental
Fig. 3A). Examination of themicrotubule scaffold through
a-tubulin staining showed unchanged overall organiza-
tion (Fig. 2D). However, in the case of H6PD silencing, the
microtubule organization center (or centrosome), from
where the fibersemanate, exhibitedamorediffusepattern.
The expression level of neither actin (Figs. 3 and 4) nor
a-tubulin (Fig. 2E) was affected by H6PD knockdown.
Finally, analysis of mRNA levels of the intermediate fila-
ment protein vimentin showed no difference after H6PD
silencing (Fig. 2C).
Decreased expression of proteins involved in
the UPR pathway upon H6PD down-regulation
In muscle cells from H6PD2/2 mice, changes in proteins
of the UPR pathway have been reported (7). Emerging
evidence strongly suggests that mild activation of the
UPR pathway is essential for cancer cell growth (25, 26).
Therefore, we investigated whether H6PD could affect
cancer cell proliferation through changes in the UPR. This
pathway consists of 3 branches, and extensive crosstalk
between components of those branches have been docu-
mented (reviewed in ref. 27). The first branch commences
with the PERK, which, upon activation through auto-
phosphorylation, promotes phosphorylation and activa-
tion of eIF2a. This factor then acts as a global inhibitor of
mRNA translation, but specifically increases translation
of certain mRNAs, predominantly that of ATF-4, which
subsequently enhances transcription of target genes, in-
cluding CHOP.
To investigate the possible involvement ofH6PD in this
pathway, we down-regulated its expression in SUM159
cells and performed Western blot analysis against PERK,
eIF2a, peIF2a, and ATF4 at 72 h after siRNA transfection
(Fig. 3A). We did not detect significant changes in PERK
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Figure 2. H6PD knockdown reduces cancer cell migration and increases cell adhesion. A) SUM159, MCF7, and MDA-MB-453
cells were transfected with mock or H6PD siRNAs, and cell migration was assessed by a migration assay. Data represent the
number of migrated cells counted after crystal violet staining in 10 independent visual ﬁelds (left) or as a percentage of migrated
cells after H6PD knockdown, compared with mock-transfected cells (right). Graphs depict the means from at least 3 independent
experiments 6 SD in SUM159 cells. mRNA analysis of the indicated genes 48 h after H6PD knockdown in SUM159 cells. B)
SUM159 cells were transfected with mock or H6PD siRNAs and reseeded after 72 h on ﬁbronectin-coated plates or were left
untreated. Adhesion was evaluated spectrometrically after crystal violet staining. Absorbance data were normalized to the values
of mock-transfected cells on ﬁbronectin-coated wells. C) qPCR analysis of mRNA levels for the depicted genes, 48 or 72 h after
siRNA transfection in SUM159 cells. D) SUM159 cells were transfected with H6PD siRNA or mock siRNA and, 72 h later, were
subjected to immunoﬂuorescence with an antibody against a-tubulin. E) Western blot analysis of a-tubulin levels in SUM159 cells
72 h after knockdown of H6PD compared to mock-transfected cells. Ns, nonsigniﬁcant. *P , 0.05, **P , 0.01, ***P , 0.001 vs.
mock siRNA.
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expression levels upon H6PD knockdown. However, we
could not find an antibody against the phosphorylated
form of PERK that worked in our hands, and therefore we
could not draw conclusions on its activation status. Al-
though total eIF2a levels were unaffected, a significant
increase in its phosphorylated form was observed after
H6PD knockdown. Although one would expect this to
result in increasedATF4 levels,weparadoxically observed
a dramatic decrease in ATF4 expression, which could
imply that higher eIF2a phosphorylation represents a
compensatory adaptation. Decreased ATF4 levels upon
H6PD silencing were also observed at the mRNA ex-
pression level (Fig. 3C).
The second branch of the UPR response includes
inositol-requiring (IRE)-1a, which, upon activation and
phosphorylation, leads to the splicing of the sXBP1, pro-
ducing the active transcription factor sXBP1, that upon
translocation to the nucleus, leads to the expression of
target genes, often involved in ERAD (28, 29). Our results
showed significantly decreased sXBP1 levels upon H6PD
knockdown(Fig. 3B). The thirdbranchof theUPRincludes
ATF-6, an ER membrane protein that upon activation
translocates to theGolgiwhere it is proteolytically cleaved.
The active transcription factor fragment of the protein is
then released and controls target gene expression in the
nucleus. Upon H6PD knockdown, we observed a signifi-
cant decrease in ATF6 expression, at both the transcrip-
tional (Fig. 3C) and protein level. In line with the above
findings, the mRNA and protein levels of CHOP, with
expression that can be induced by bothATF4 and -6,were
significantly decreased (Fig. 3B, C). These results point
toward an attenuation of all branches of the UPR upon
H6PD silencing. To test whether the observed differences
are caused by the decreased cell proliferation, we per-
formed the same experiments 42 h after H6PD knock-
down, at a time point before the proliferation of the
SUM159 cells was affected. We obtained identical results
for ATF4 and CHOP at 72 h, suggesting that the re-
duction in the expression levels of these 2 transcription
factors precedes the decrease in cell proliferation
(Supplemental Fig. 4). ATF6 expression tended to de-
crease 42 h after H6PD knockdown, whereas sXBP1
levels were unchanged.
Effect of H6PD knockdown on the protein-
folding machinery
The UPR response can be elicited by a variety of stimuli,
including defects in protein folding or protein-folding
overload in the ER. To investigate whether the observed
differences after H6PD down-regulation in the UPR pro-
tein levels are a consequence of changes in protein folding,
we analyzed the expression of members from the 3 main
protein-folding families (30, 31). First, we examined the
heat-shock proteins Grp94 (the ER paralogue of cytosolic
heat shock protein 90) andGrp78.We found no difference
in the levels ofGrp94afterH6PDsilencing, comparedwith
mock-transfected SUM159 cells, whereas Grp78 expres-
sion was slightly reduced (Fig. 4A). Next, we tested the
expression of members of the PDI family. H6PD knock-
down caused no change in the expression of PDI and
Figure 3. Alterations in UPR signaling after
H6PD silencing. SUM159 cells were mock or
H6PD siRNA transfected. A, B) Western blot
analysis was performed at 72 h after transfection
for semiquantitative analysis of protein levels of
PERK, eIF2a, peIF2a, and ATF4 (A) and ATF6,
sXBP1, and CHOP (B). A representative
Western blot image is shown (left) in addition
to the relative protein levels measured from 3
independent experiments by densitometric
analysis of the bands after normalization to
actin loading control levels (right). C) mRNA
expression of ATF4, ATF6, and CHOP 72 h
after H6PD down-regulation compared to
mock-transfected cells, as assessed through
qPCR. Values were normalized to the levels of
the gene prolyl cis-trans isomerase A. Ns,
nonsigniﬁcant. *P , 0.05, **P , 0.01, ***P ,
0.001 vs. mock siRNA.
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ERp44, but there was a small but significant increase in
ERp72 levels (Fig. 4B). Finally, we tested the expression of
calreticulin and calnexin, which serve as molecular chap-
erones forglycoproteins in theER.H6PDdown-regulation
caused a significant increase in calreticulin levels, whereas
calnexin expression was unchanged (Fig. 4C).
H6PD silencing alters SERCA2 and IP3RIII
expression and increases intraluminal Ca2+
The 2 calcium-binding proteins calreticulin and ERp72
were the only ones of all the ER chaperones examined that
exhibited a significant increase in their expression after
H6PD knockdown. This result led us to test a potential
effect of H6PD down-regulation on proteins responsible
for maintaining ER calcium homeostasis. H6PD silencing
in SUM159 cells caused a significant increase in SERCA2
expression, which mediates calcium transport from the
cytosol into the ER (Fig. 5A). This increase was observed
both after 42 h, before a significant difference in cell pro-
liferation could be detected, and after 72 h of siRNA
treatment, but reached statistically significant levels only
after 72 h. Furthermore, the levels of the IP3RIII, which is
responsible for calcium export from the ER, were signifi-
cantly reduced both 42 and 72 h after H6PD knockdown
(Fig. 5A). We reasoned that the increased SERCA2 levels,
together with decreased IP3RIII expression upon H6PD
silencing, may be caused by an increase in ER calcium
concentrations. Alternatively, H6PD knockdown could
lead to an ER-to-cytoplasm calcium leak, which may be
compensated for by the observed changes in SERCA2 and
IP3RIII expression. To discriminate between the 2 poten-
tial mechanisms, wemonitored ER luminal calcium levels
by using the FRET-based indicator D1ER (21). This sensor
enables live measurements of calcium in individual cells.
The critical point in using fluorescent calcium indicators is
the calibration of the sensor for each cell measured.
Therefore, a calibration protocol has to be developed for
every cell line to determine the minimum and maximum
calcium-binding capacity of the sensor. For the SUM159
cell line, to reach theminimumFRET ratio (FRET:CFP), 10
mM ionomycin and 5 mM EGTA in calcium-free buffer
were used,whereas to reachmaximumFRET ratio, 10mM
ionomycin and 5 mM CaCl2 were used (for details, see
Materials and Methods). We observed a significant in-
crease in FRET efficiency both at 42 and 72 h after H6PD
knockdown, which translates into increased ER luminal
calcium concentrations, starting at least 42 h after siRNA
treatment (Fig. 5B). To examine whether this increase
could be related to reduced calcium release from the ER,
we treated cells with the cytosolic calcium indicator
FLUO-4 AM (Thermo Fisher Scientific) and monitored
fluorescence in steady state and after addition of Cch,
which induced release fromERcalciumstores through IP3
receptors. From these experiments, we cannot report ab-
solute cytosolic calcium levels, because no calibration of
the systemwas performed.We observed that, after H6PD
down-regulation, there was a significant decrease in the
difference between fluorescence intensity at baseline and
Figure 4. Effect of H6PD knockdown on ER
folding proteins. H6PD or mock-transfected
SUM159 cells were analyzed by Western blot, as
in Fig. 3, for estimation of levels of the heat
shock family proteins Grp94 and -78 (A), the
PDI family proteins PDI, ERp44, and ERp72
(B) and the chaperones calreticulin and
calnexin (C). Ns, nonsigniﬁcant. *P , 0.05 vs.
mock siRNA.
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after Cch addition (Fig. 5C), suggesting defective calcium
efflux from the ER.
Down-regulation of H6PD leads to an
increased oxidation state in the ER lumen and
superoxide production in mitochondria
It is known that the environment in the ER is more ox-
idized than in the cytosol, thereby supporting oxidative
protein folding (19, 32). The redox conditions in the ER
and theUPRmachinery are unambiguously linked (33).
Furthermore, recent findings suggest that ER calcium
signaling proteins are also affected by the ER redox
status (34). Because H6PD knockdown leads to de-
creased NADPH content in the ER lumen, we in-
vestigated whether this would cause a change in the ER
redox environment that could offer a link to the ob-
served UPR and calcium changes. To assess the ER
oxidation status, we used an ER-targeted roGFP,
roGFP1iEER. The challengewith roGFP sensors targeted
to the ER lumen is that they exhibit a high degree of
oxidation at steady levels, because of the highly oxi-
dized environment in the ER lumen. This renders
measurement of changes toward an increase of oxida-
tion particularly challenging. The choice of roGFP1-
iEER was based on the fact that it was the least oxidized
ER-specific roGFP sensor among a series of constructs
reported earlier (19). The ratio of fluorescence intensity
emission after excitation at 405 and 440 nm at steady
state, after complete oxidation (diamide addition) and
complete reduction (DTT addition) of the sensor, en-
ables the calculation of the OxD value, representing the
degree of oxidation. Live-imaging experiments were
performed starting 48 or 72 h after mock- or H6PD-
siRNA transfection in SUM159 cells, and the OxD val-
ues were calculated after measurements of fluorescent
emission intensities in individual cells. At 48 h after
knockdown, we observed a significant increase in oxi-
dation upon H6PD silencing, which was no longer ev-
ident at 72 h. This finding is depicted by both the
fluorescence ratio in the 3 oxidation states of the sensor
and the OxD values (Fig. 6A).
Next, we asked whether the increase in ER oxidation
would lead to augmented production of reactive oxygen
species (ROS). Unfortunately, we were not able to success-
fully implement the ER-specific hyper probe in our cell
system (35). Given the physical and functional connection
between the ER and mitochondria, we next tested whether
ROS content in mitochondria could be affected by H6PD
down-regulation. For this purpose, we used the mitochon-
drial superoxide anion indicator MitoSOX Red. We found
that, at both 48 and 72 h after knockdown, baseline levels of
superoxide were higher in the H6PD siRNA-transfected
cells (Fig. 6B). This difference increased over time under the
constant presence of a stressor that augmentsmitochondrial
Figure 5. H6PD knockdown alters the expres-
sion of ER calcium transporters and intraluminal
calcium concentrations. A) The expression of
SERCA2 and IP3RIII was analyzed by Western
blot 42 and 72 h after siRNA treatment in
SUM159 cells. B) ER luminal calcium concentra-
tions were measured 42–46 and 68–72 h after
H6PD knockdown by using the D1ER probe. In
total, 35–40 single cells were imaged per condi-
tion in 3 independent experiments. The graphs
depict the mean 6 SD of DR values after baseline
measurements, followed by calibration of the sensor
with ionomycin (Ion)/EGTA for Rmin determina-
tion, and subsequent addition of Ion/5 mM CaCl2
for Rmax determination. A representative plot of
the FRET ratio (FRET:CFP) is shown at the bottom
of each graph. C) At 72 h after transfection with
the indicated siRNAs, SUM159 cells were incubated
with FLUO-4 AM. Fluorescence was measured in
real-time at steady state and after addition of Cch.
At the top of the panel the normalized values of the
difference in ﬂuorescence intensity before and
after Cch treatment are depicted, and at the
bottom, the actual measurement during a repre-
sentative experiment. Ns, nonsigniﬁcant. *P, 0.05,
**P , 0.01, ***P , 0.001 vs. mock siRNA.
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superoxide production (15% ethanol). The above findings
imply that silencing of H6PD expression causes elevated
ROS production in mitochondria.
Impact of H6PD knockdown on
energy metabolism
Previouswork showed thatH6PDdown-regulation in 2
murine cancer cell lines decreased overall ATP levels,
without affecting mitochondrial oxygen consumption.
In addition, supernatant lactate concentration, in-
dicative of glycolysis, was found to be decreased (9). In
the present study, measurement of total ATP levels in
correlationwith the total number of cells in the SUM159
cell line, did not show statistically significant changes
betweenmock- andH6PD siRNA–treated cells at 24, 48,
and 72 h after transfection, although the levels tended to
be higher for the cellswhereH6PDwasdown-regulated
(Supplemental Fig. 3B). To assess specific aspects of
energy metabolism in the 3 selected human breast
cancer cell lines, we performed real-timemeasurements
of OCR (indicative of mitochondrial respiration) and
ECAR at steady state levels and after application of
antimycin and FCCP according to the Seahorse manu-
facturer’s protocol (Agilent Technologies). Antimycin
inhibits the electron transport chain in mitochondria,
provoking a concomitant increase in glycolysis. FCCP is
an uncoupler of oxidative phosphorylation in mito-
chondria and drives a compensatory increase in oxy-
gen consumption. Combination of both substances is
expected to raise both OCR and ECAR levels, allowing
for estimation not only of the steady state of cells, but
also of their metabolic potential after stress. It should be
noted that OCR is a good indicator of oxidative phos-
phorylation, but enzymatic oxygen consumption not
related tomitochondrial respiration could account for a
small percentage of our measurements and cannot be
discriminated with the assay used. We found that
H6PD knockdown in SUM159 cells led to decreased
OCR 48 h after transfection, which was more pro-
nounced after stress (Fig. 7A). This effect was reversed
72 h after knockdown, where a rise in OCR levels was
observed after H6PD knockdown, indicating the pres-
ence of a compensatorymechanism. On the other hand,
MDA-MB-453 cells exhibited a decreased OCR, both at
baseline and stressed levels, only 72 h after H6PD si-
lencing. ECAR levels were not significantly affected
in SUM159 cells 48 h after H6PD down-regulation,
whereas an increase was observed after 72 h (Fig. 7B).
In contrast, reduced ECAR, which was statistically
significant only after stress, was detected in MDA-MB-
453 cells. Although glycolysis is the main reason for
medium acidification, other sources may contribute to
the extracellular proton concentration. To confirm that
the ECAR measurements mirror changes in glycolysis
in our cell systems, we studied at steady state levels the
expression of 2 conventional markers of glycolysis,
hexokinase-1, andATP-dependent 6-phosphofructokinase,
liver type, (Supplemental Fig. 3C). We showed that, at
48 h after H6PD silencing in the SUM159 cells, the
levels of both enzymes were unaltered, whereas an
Figure 6. Silencing of H6PD leads to an increase in the ER redox status and mitochondrial superoxide levels. A) SUM159 cells
were transfected with mock or H6PD siRNAs, and redox changes were observed 48 and 72 h after treatment, using the ER-
targeted ratiometric probe roGFP1-iEER. The OxD value was determined from the ratios of ﬂuorescence emission intensities after
excitation at 405 and 488 nm. Means6 SD were calculated from 3 independent experiments. Representative graphs of the ratio of
ﬂuorescence intensities at baseline, after full oxidation and full reduction of the sensor are shown from 2 H6PD- and 2 mock-
siRNA–transfected cells at each time point. B) H6PD was down-regulated in SUM159 cells, and 48 or 72 h later, superoxide levels
were monitored using the red indicator under normal conditions or after addition of ethanol as stressor. The measurements were
performed in real time by using high-throughput imaging, and the values represent the mean of 3 independent experiments.
Baseline and stressed levels were documented in each experiment and are shown separately for better comprehension of scale.
For simplicity, only the statistical signiﬁcance of the latest time point is depicted in every graph. Ns, nonsigniﬁcant. **P , 0.01,
***P , 0.001 vs. mock siRNA.
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increased expression was observed at 72 h. These re-
sults are consistent with the baseline ECAR measure-
ments for this cell line at the 2 time points (Fig. 7B).
DISCUSSION
The cytosolic pentose phosphate pathway produces re-
ducing equivalents in the form of NADPH, as well as
pentoses, including the nucleotide precursor ribose 5-
phosphate. The first step in this metabolic cascade is the
conversion of glucose 6-phosphate to 6-phosphoglucono-
lactone, with concomitant NADPH production, and it is
performedbyG6PD. The ER equivalent ofG6PD isH6PD,
and it is the only well-characterized enzyme known so far
to produce NADPH within the ER. A latent 6-phospho-
gluconate dehydrogenase activity generating NADPH in
the ER lumen has been observed in isolated rat liver mi-
crosomes [(36) and Legeza and Odermatt, unpublished
observations]; however, the gene encoding this enzyme
has not yet been identified. In addition, although evidence
of the existence of other downstream components of the
pentose phosphate pathway in the ER has been provided
(37), the genes corresponding to the observed enzymatic
activities remain to be discovered. Therefore, whether the
ER contributes to total cellular ribose production through
an independent pentose phosphate pathway, thereby af-
fectingATPproduction, remainsunclear.Establishmentof
a reliable method for measurement of ribose levels in the
ERcouldpartially address this central question.Becauseof
poor membrane permeability, the ER pool of NADPH is
maintained independent of that in the cytosol. To date,
11b-HSD1 represents the only enzyme that has un-
deniably been shown to use NADPH as a cofactor in the
ERand toperformareductive reaction. 11b-HSD1,known
to catalyze the oxoreduction of cortisone as well as that
of 7-ketocholesterol and 7-ketolithocholic acid (38), is
expressed in only 1 of the 3 cell lines investigated in the
present study (SUM159) and thus cannot explain the ef-
fects of H6PD knockdown on the proliferation and mi-
gratory potential of the 3 different breast cancer cell lines.
This finding renders the importance of luminal NADPH
production by H6PD enigmatic. In the current study, we
showed that H6PD supports proliferation in 3 different
breast cancer cell lines. Whether the impact of H6PD
knockdown on proliferation is caused by lack of luminal
Figure 7. Changes in energy metabolism after H6PD knockdown. OCR (A) and ECAR (B) were measured 48 and 72 h after
H6PD knockdown in SUM159 and MDA-MB-453 cells. Three baseline measurements were performed followed by treatment with
oligomycin/FCCP and 5 additional measurements. In each case, a representative real-time measurement is shown (left), in
addition to the values of OCR and ECAR from 3 independent experiments normalized to the baseline levels of mock-transfected
cells (right). Ns, nonsigniﬁcant. *P , 0.05, **P , 0.01 vs. mock siRNA.
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NADPH or impaired formation of products of the ER lu-
minal pentose phosphate pathway is not known. Forty-
eight hours after H6PD knockdown, key CCNs for cell
cycle progression exhibited reduced expression, and a
higher percentage of cells were at the G1 phase. G1 block
after H6PD down-regulation has been reported before,
albeit with a more pronounced difference (9). In the latter
study, the time point after knockdown was not reported,
and at the time of the experiment,most of the cells were in
theG1phase.Theseparameters couldaffect themagnitude
of the observed effect.
Furthermore,we found that silencing ofH6PD causes a
dramatic decrease in cancer cell migration. Reduced mi-
gration was accompanied by an increase in cell adhesion.
The mRNA levels of MMP1 and b-catenin (which tran-
scriptionally regulates MMP1) (23) were decreased 48 h
after H6PD knockdown, consistent with stronger adhe-
sion of cells to the extracellular substrate. However, all 3
MMPs tested (MMP1, -2, and 14)were up-regulated at the
mRNA level 72 h after H6PD down-regulation. This
finding could be attributable to an attempt of the cells to
balance increased adhesion after H6PD knockdown. In
this case, the reduction of b-catenin could be the primary
effect.MMPs are known to be regulated atmultiple levels,
including proteolysis of precursor proteins (pro-MMPs)
and regulation of activity through tissue inhibitors of
metalloproteinases [reviewed in (39)]. Therefore, elevated
MMPmRNAlevels could alternativelybe a compensatory
mechanism for reduced pro-MMP cleavage or MMP
activity. Upon H6PD silencing, we observed a loose
appearance of the centrosome, as visualized through
a-tubulin immunofluorescence staining. Microtubule
structure is indispensable for cell movement (40), and
changes in the centrosome have been reported to cause
defects in cell migration (41, 42).More detailed studies on
the structure and composition of the microtubular net-
work after H6PD down-regulation will provide a clearer
picture.
Mice lackingH6PDpresentwith skeletalmuscledefects
and muscles cells from these animals exhibited increased
Grp78 protein expression, in addition to alterations in
different UPR proteins, as shown by microarrays, in-
cluding an induction of CHOP (7). To characterize the role
of H6PD in cancer cell proliferation and migration, we
analyzed the cellular changes after H6PD silencing. A
detailed analysis in our SUM159 breast cancer cell system
of key proteins involved in the 3 different UPR branches
showeddecreased expression of the chaperoneGrp78 and
the transcriptions factors ATF4, ATF6, sXBP1, andCHOP.
The reduction in ATF4 and CHOP expression preceded
thedecreasedproliferation, indicating that these factorsact
upstream of the latter event. Those findings point toward
a role of H6PD in pathways activating ATF4, which
most typically involve oxidative damage and amino acid
depletion (43). Using the roGFP1iE-ER sensor in live
single-cell measurements, we demonstrated that H6PD
knockdown provoked an increased oxidation state in the
ER lumen, which was present 48 h after knockdown and
returned to basal levels after 72 h, suggesting the ability of
the cells to reverse this imbalance.H6PDdown-regulation
also caused an increase inmitochondrial superoxide levels,
reiterating the notion that changes in ERhomeostasis affect
mitochondrial function (44, 45).
Because there is extensive crosstalk among the 3 UPR
pathways, it is critical to clarify which are the initial UPR
components affected: ATF4 promotes CHOP and XBP1
expression (46, 47), and ATF6 induces transcription of
XBP1 (48). Nonetheless, the 3 UPR branches are re-
sponsive todifferent stimuli anddedicated to regulationof
diverse cellular functions. The specific molecules and
pathways affected by the reduction in the levels of ATF4,
ATF6, CHOP, and sXBP1 after H6PD down-regulation
necessitate further analysis. Among several interesting
candidates are autophagy-related genes controlled by
ATF4 andCHOP (such as,ATG5,ATG12, andP62) (49, 50)
and ERAD-associated genes regulated by XBP1, ATF6,
or both, including ER degradation-enhancing a-man-
nosidase-like protein and DnaJ homologue subfamily B
member 9 (51, 52). Furthermore, themetastasis-promoting
factors VEGFA and lysosomal-associated membrane
protein-3) are activated by ATF4 and are likely to be af-
fected after H6PD knockdown (53, 54).
The reliance of cancer cells on the UPR pathway has
been well established, and increased levels of critical UPR
components have been shown in a multitude of human
cancer tissues, including those originating in breast, colon,
lung, pancreas, skin, prostate, andbrain (25, 26, 55, 56). It is
conceivable that constitutive UPR activation is important
for excessive cell proliferation, which is coupled to high
rates of protein synthesis and demand for protein-folding
regulation. Moreover, cancer cells are often forced to sur-
vive in conditions of hypoxia and nutrient depletion,
which drives them to harness the UPR system for coun-
terbalancing these harsh conditions. Therefore, the UPR
could well represent the Achilles’ heel in malignant cell
growth, and therapeutic strategies to target this pathway
are currently being explored (57–59). This strategy in-
volves both attempts to overactivate and inhibit the UPR.
For example, several compounds targetingeither theATP-
binding pocket or the RNase domain of IRE1, and thereby
reducing XBP1 mRNA cleavage, have been developed,
and encouraging results in preclinical studies for multiple
myeloma have been reported (60, 61). The PERK-eIF2a-
ATF4 pathway has also attracted considerable attention,
with recently developed PERK inhibitors showing prom-
ising antitumor effects inmousemodels (62, 63). In light of
theabove, identificationofH6PDasamodulatorofUPR in
cancer cells is of particular interest and offers a potential
therapeutic target, especially in view of the mild pheno-
type reported in mice lacking H6PD.
In an attempt to elucidate the mechanism underlying
the attenuationofUPRafterH6PDsilencing,weexamined
a potential involvement of impaired protein folding. We
foundsignificantly increased levelsof calreticulin,acalcium-
bindingprotein that surveilsproper foldingofglycoproteins
in theER lumenbeforeexit to theGolgi (64). In addition, the
levels of ERp72, a PDI family member that catalyzes
disulfide bond formation and contains a calcium-binding
domain,were increased (65). Becauseof the changes in the
2 calcium-binding chaperones,we investigated the impact
of H6PD on ER calcium homeostasis and found increased
IP3RIII expression after 42 h of H6PD knockdown, a time
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point preceding the reduced cell proliferation. SERCA2
expression was significantly up-regulated after 72 h of
H6PD down-regulation. IP3RIII is responsible for cal-
cium export from the ER, whereas SERCA2 imports
calcium from the cytosol into the ER. Reduced SERCA2
expression has been reported in many types of human
cancer, including oral and thyroid cancer (66, 67), which
raises the possibility that the ER calcium content in
cancer cells at steady state is lower than that of normal
cells. Live measurements of calcium in the lumen of the
ER using the D1ER FRET-based sensor indicated in-
creased calcium levels after H6PD knockdown, begin-
ning at 42 h after knockdown and persisting at least until
72 h. Although this increase occurred soon after H6PD
down-regulation, further experiments are needed to learn
whether this is a primary effect caused by reduced H6PD
expression or a compensation for a presumptive calcium
leak. Our experiments revealed attenuated ability of cal-
cium release from the ER upon Cch addition after H6PD
down-regulation. Whether the changes in calcium have a
causative role in the observed UPR alterations or are a
consequence of those remains to be determined. Devia-
tions fromnormal calciumconcentrations in theER lumen
are likely to influence both cancer cell proliferation and
migration, because calcium signaling has been shown to
play a paramount role in cancer cell survival (68).
According to a previous study, knockdown ofH6PDin
2murine cancer cell lines causeda reduction inATPcontent,
whichwasattributedtoareduction inglucoseconsumption,
whereas no difference in oxidative phosphorylationwas
observed (9). In the present study, in analyzing SUM159
cells, we did not find differences in totalATP levels after-
H6PDdown-regulation.As different cancer cells can display
profound differences in their metabolic capacity and in us-
ing different energy sources, we determinedthe impact
ofH6PDknockdown on energy metabolism in the 2 breast
cancer cell lines SUM159 and MDA-MB-453, both in their
basal state and under stressed conditions by treatmentwith
the mitochondrial electron transport chain inhibitor anti-
mycin and the oxidative phosphorylation uncoupler FCCP.
Comparison of the baseline and stressed phenotype pro-
vides insight into the metabolic potential of each cell line.
Knockdown of H6PD led to increased ECAR in the
SUM159 cells and decreased OCR in the MDA-MB-453
cells at steady state. Analysis of the rate of OCR/ECAR
utilization (Supplemental Fig. 3D) showed that the SUM159
cells equally depend on both sources, whereas the MDA-
MB-453 cell line mostly uses oxidative phosphorylation in
comparison to glycolysis for energy production. Our results
indicate that a main energy source is affected in both cases.
The increased ECAR in SUM159 cells 72 h after H6PD
knockdown, which could be caused by a compensatory
capacity of this cell line, makes interpretation of ECAR re-
sults difficult, warranting further investigation. Because the
MDA-MB-453 cells did not show differences in basal levels
of glycolysis after H6PD knockdown, our study is in-
conclusive as to whether H6PD is generally involved in
glucose metabolism. After stress, the SUM159 cells also
exhibited a reducedOCR48h afterH6PDdown-regulation,
which was observed in the MDA-MB-453 cells after 72 h
undernormal andstressedconditions.This finding suggests
that the SUM159 cell line is resistant to changes inOCR, and
differences are seenonly after stress.Moreover, the SUM159
cells exhibit significantly increased oxygen consumption
only after stress 72 h after H6PD silencing, which could
represent a compensatory mechanism related to defects in
oxidative phosphorylation. The MDA-MB-453 cell line
demonstrates a great metabolic glycolytic potential after
stress, which was shown to be reduced after H6PD knock-
down.Our findingspoint towardanunanticipatedchange in
energy metabolism after H6PD down-regulation. It is possi-
ble that the effects ofH6PDonenergymetabolism, especially
regarding OCR, are linked with the altered ER redox envi-
ronment, or the increased ROS production in mitochondria
(Fig. 6). In SUM159 cells after 48 h of H6PD knockdown,
before possible compensatory adaptations, OCR decreased
upon treatment with the stressors antimycin and FCCP,
whereas superoxide production increased both under basal
conditions and after exposures to ethanol as a stressor. This
effect suggests a real reduction in oxidative phosphoryla-
tion activity, greater than that indicated by the OCR mea-
surement. Given the flexibility in energy source utilization
by cancer cells, further investigation into this topic requires
extensive understanding of energymetabolism in each cell
system. Itneeds tobenoted, that themetabolicpathwaysof
different breast cancer cell lines might be profoundly
influenced by the culture conditions and medium compo-
sition,whichmay contribute to the differences inOCR and
ECAR observed in the present study and that they may
differ from those in patient’s breast tumor cells.
The results presented highlight the importance of
NADPH production in the ER through H6PD for cancer
cells. We demonstrated a significant role for H6PD in
promoting cell proliferation andmigration. Moreover, we
described the cellular changes after H6PD silencing that
could underpin these effects, including an increased ER
luminaloxidation statewithin theER,anattenuationof the
UPR pathway and an increase in ER calcium concentra-
tions. The ER is a dynamic organelle where vital functions
takeplace, encompassing, amongothers, protein synthesis
and quality control, lipid synthesis, and calcium signaling.
Our study opens new avenues into understanding how
compromised ER homeostasis influences cancer cell
physiology and proposes H6PD as a potential novel
therapeutic target against cancer.
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